Publication Name	World Journal of Pharmacology
Manuscript ID	22765
Country	France

Received	2015-09-23 08:29
Peer-Review Started	2015-10-06 01:06
To Make the First Decision	2015-10-27 10:48
Return for Revision	2015-10-30 10:14
Revised	2015-11-19 21:31
Second Decision	2015-12-07 09:34
Accepted by Journal Editor-in-Chief	2015-12-08 17:08
Accepted by Company Editor-in-Chief	2015-12-14 17:58
Articles in Press	2015-12-14 17:58
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-02-24 17:29
Publish the Manuscript Online	2016-03-04 15:35

ISSN	2220-3192 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Adalimumab and pharmacokinetics: Impact on the clinical prescription for inflammatory bowel disease
Manuscript Source	Invited Manuscript
All Author List	Anne-Laure Pelletier and Pascale Nicaise-Roland
Funding Agency and Grant Number
Corresponding Author	Anne-Laure Pelletier, MD, Hospital Practitioner, Department of Hepato-Gastroenterology, Hôpital Bichat-Claude Bernard, 46 rue Huchard, 75018 Paris, France. anne-laure.pelletier@bch.aphp.fr
Key Words	Pharmacokinetics; Adalimumab; Crohn’s disease
Core Tip	We have reviewed all the recent data about the factors that influence Adalimumab pharmacokinetics and the impact for the clinicians in the assessment of inflammatory disease. We looked at the inter patient variability, the drug clearance, antibodies detection, the effect of concomitant use of immunosuppressive.
Publish Date	2016-03-04 15:35
Citation	Pelletier AL, Nicaise-Roland P. Adalimumab and pharmacokinetics: Impact on the clinical prescription for inflammatory bowel disease. World J Pharmacol 2016; 5(1): 44-50
URL	http://www.wjgnet.com/2220-3192/full/v5/i1/44.htm
DOI	http://dx.doi.org/10.5497/wjp.v5.i1.44

Full Article (PDF)	WJP-5-44.pdf
Full Article (Word)	WJP-5-44.doc
Manuscript File	22765-Review.docx
Answering Reviewers	22765-Answering reviewers.pdf
Audio Core Tip	22765-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	22765-Conflict-of-interest statement.pdf
Copyright License Agreement	22765-Copyright assignment.pdf
Peer-review Report	22765-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	22765-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	22765-Scientific misconduct check.pdf
Scientific Editor Work List	22765-Scientific editor work list.pdf